Regeneron expects $127 million IPR&D charge in Q2 2026

Regeneron Pharmaceuticals disclosed in a Form 8-K dated July 6, 2026 that it anticipates recording an acquired in-process research and development charge of roughly $127 million before taxes when it reports second quarter 2026 results. Regeneron Pharmaceuticals, Inc. currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles and its non-GAAP financial results for the second quarter 2026 will include an acquired in-process research and development charge of approximately $127 million on a pre-tax basis.¹

The company attributed the charge to payments made under collaboration and licensing arrangements. This charge relates to up-front and opt-in payments in connection with collaboration and licensing agreements.¹ Regeneron said the hit would lower per-share earnings by about a dollar under both accounting methods for the quarter. The acquired IPR&D charge is expected to negatively impact each of GAAP and non-GAAP net income per diluted share for the second quarter 2026 by approximately $1.00.¹

The filing noted that such charges can stem from several types of transactions, including asset purchases, up-front and opt-in fees, milestone payments tied to development progress, and premiums on equity tied to partnership deals. Acquired IPR&D charges may include IPR&D acquired in connection with asset acquisitions as well as up-front, opt-in, certain development milestone payments, and premiums paid on equity securities related to collaboration and licensing agreements.¹ Regeneron said it does not provide forward guidance on these charges because it cannot predict when such deals will happen or how large they will be. Regeneron does not forecast such acquired IPR&D charges due to the uncertainty of the future occurrence, magnitude, and timing of these transactions in any given period.¹

The company cautioned that the figures are preliminary. Regeneron’s results for the second quarter 2026 have not been finalized and are subject to Regeneron’s financial statement closing procedures, and there can be no assurance that actual results will not differ from the preliminary estimates described.¹ The filing did not include other pipeline updates, trial data, or cash position figures.